| scholarly article | Q13442814 |
| P50 | author | Tim Morris | Q42652887 |
| Matthew R Sydes | Q44571830 | ||
| P2093 | author name string | Mahesh K B Parmar | |
| P2860 | cites work | Why most published research findings are false | Q21092395 |
| Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design | Q24569560 | ||
| Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R | Q30357731 | ||
| The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies | Q33617148 | ||
| Assessing potential sources of clustering in individually randomised trials | Q34670307 | ||
| Variance reduction in randomised trials by inverse probability weighting using the propensity score | Q34844677 | ||
| Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers | Q34996360 | ||
| EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment | Q35005741 | ||
| A re-randomisation design for clinical trials | Q35834036 | ||
| Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative | Q36265620 | ||
| Leveraging prognostic baseline variables to gain precision in randomized trials | Q37246685 | ||
| Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review | Q38210083 | ||
| Methodology of clinical trials for rare diseases | Q38224081 | ||
| Innovative research methods for studying treatments for rare diseases: methodological review | Q38271185 | ||
| Research methods to change clinical practice for patients with rare cancers. | Q38730151 | ||
| New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study | Q38888445 | ||
| Bayesian methods for the design and interpretation of clinical trials in very rare diseases | Q41908823 | ||
| Medical research: Trial unpredictability yields predictable therapy gains | Q42920052 | ||
| Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial | Q46221067 | ||
| Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer | Q47768935 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 183 | |
| P577 | publication date | 2016-11-25 | |
| P1433 | published in | BMC Medicine | Q4835947 |
| P1476 | title | How do you design randomised trials for smaller populations? A framework | |
| P478 | volume | 14 |
| Q42363435 | A framework: make it useful to guide and improve practice of clinical trial design in smaller populations |
| Q58695016 | A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial |
| Q47160419 | A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome? |
| Q91949479 | An evaluation of inverse probability weighting using the propensity score for baseline covariate adjustment in smaller population randomised controlled trials with a continuous outcome |
| Q59136188 | Applicability and added value of novel methods to improve drug development in rare diseases |
| Q45943629 | Fact or fiction: reducing the proportion and impact of false positives. |
| Q64039462 | Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study |
| Q38735691 | Physical Activity Self-Management and Coaching Compared to Social Interaction in Huntington Disease: Results From the ENGAGE-HD Randomized, Controlled, Pilot Feasibility Trial |
| Q47158264 | Physical Therapy and Exercise Interventions in Huntington's Disease: A Mixed Methods Systematic Review |
Search more.